Entrada Therapeutics (TRDA) Invested Capital (2020 - 2026)

Entrada Therapeutics' Invested Capital history runs 7 years deep, the most recent figure standing at $270.9 million for Q1 2026.

• In Q1 2026, Invested Capital fell 35.09% year-over-year to $270.9 million; the TTM figure through Mar 2026 stood at $270.9 million (down 35.09% YoY), while the FY2025 annual figure was $306.1 million, down 28.59% from the prior year.
• Invested Capital was $270.9 million for Q1 2026 at Entrada Therapeutics, down from $306.1 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $429.9 million in Q2 2024 to a low of $206.9 million in Q2 2023.
• Historically, Invested Capital has averaged $304.1 million across 5 years, with a median of $270.9 million in 2026.
• The sharpest annual moves came in 2022 and 2026: Invested Capital soared 658.48% in 2022, then slumped 35.09% in 2026.
• A 5-year view of Invested Capital shows it stood at $212.6 million in 2022, then increased by 14.02% to $242.4 million in 2023, then jumped by 76.88% to $428.7 million in 2024, then decreased by 28.59% to $306.1 million in 2025, then slipped by 11.52% to $270.9 million in 2026.
• The last three Invested Capital figures came in at $270.9 million (Q1 2026), $306.1 million (Q4 2025), and $340.7 million (Q3 2025), per Business Quant data.